{"clarifying_information": [{"clarifying_question1": "Are you interested in the specific economic advantages of using E. coli for large-scale industrial production of recombinant proteins compared to other hosts like yeast or mammalian cells?", "clarifying_answer1": {"clarifying_answer": "Yes, I am interested in the specific economic advantages of using E. coli for large-scale industrial production of recombinant proteins, especially in comparison to other hosts like yeast or mammalian cells."}}, {"clarifying_question2": "Do you want detailed information about the technical and genetic advantages of E. coli, such as ease of genetic manipulation or its extensive molecular toolkit for protein expression?", "clarifying_answer2": {"clarifying_answer": "Yes, I would like detailed information about the technical and genetic advantages of E. coli, including ease of genetic manipulation and its molecular toolkit for protein expression."}}, {"clarifying_question3": "Are you seeking to understand the growth characteristics of E. coli\u2014such as its fast doubling time and high cell density\u2014and how these contribute to its efficiency for recombinant protein production?", "clarifying_answer3": {"clarifying_answer": "Yes, I am interested in how the rapid growth rate and ability to reach high cell density in E. coli contribute to its efficiency and advantages as a host for recombinant protein production."}}], "better_query": "What are the specific economic advantages of using Escherichia coli as a host for large-scale industrial recombinant protein production compared to alternative hosts such as yeast or mammalian cells?", "better_answer": {"sections": [{"title": "Introduction to Recombinant Protein Production Systems", "tldr": "Escherichia coli (E. coli) is one of several host organisms used for industrial recombinant protein production, alongside yeast, mammalian cells, and insect cells. E. coli stands out as an economically advantageous system due to its well-characterized genetics, rapid growth, and simplified cultivation requirements. (LLM Memory)", "text": "\nRecombinant protein production involves the expression of foreign genes in host organisms to manufacture proteins of interest for pharmaceutical, industrial, or research applications. Several expression systems have been developed for this purpose, with E. coli being one of the most widely used bacterial hosts. Other common production platforms include yeast systems (such as Saccharomyces cerevisiae and Pichia pastoris), mammalian cell lines (like Chinese Hamster Ovary cells), and insect cell systems.\n\nE. coli has emerged as a preferred host for many industrial applications due to several economic advantages. As a prokaryotic organism, E. coli has relatively simple genetics that have been extensively studied and characterized over decades of research. This bacterial system offers rapid growth kinetics with doubling times as short as 20 minutes under optimal conditions, allowing for quick biomass accumulation and protein production. The cultivation media for E. coli are typically inexpensive, consisting of simple carbon sources and minimal nutrient requirements compared to the complex and costly media needed for mammalian cell culture.\n\nThe economic appeal of E. coli also stems from its ability to achieve high cell densities in bioreactors and its capacity for high-level protein expression, with recombinant proteins sometimes accounting for up to 50% of the total cellular protein. These factors contribute to higher volumetric productivity and lower production costs compared to eukaryotic expression systems. Additionally, the well-established genetic tools and expression vectors available for E. coli facilitate straightforward genetic manipulation and process development, further reducing the economic barriers to industrial-scale production. <Model name=\"Anthropic\" version=\"claude-3-7-sonnet-20250219\">", "citations": [], "table": null}, {"title": "Cost-related Production Advantages", "tldr": "E. coli offers significant economic benefits for recombinant protein production through its inexpensive cultivation requirements, high productivity, and streamlined processing compared to eukaryotic hosts like mammalian cells and yeast. (13 sources)", "text": "\nE. coli stands out as the most cost-effective expression system for large-scale industrial recombinant protein production, with economic advantages that span multiple aspects of the manufacturing process. A primary cost benefit is the simplicity and affordability of growth media. Unlike mammalian cell lines that require complex and expensive media components, E. coli can be cultivated on relatively cheap defined media consisting of simple carbon sources such as glucose, ammonia phosphate, and basic minerals <Paper corpusId=\"275819850\" paperTitle=\"(Casteleijn et al., 2025)\" isShortName></Paper>. This fundamental difference in nutritional requirements substantially reduces raw material costs in industrial-scale production.\n\nThe economic efficiency of E. coli is further enhanced by its rapid growth kinetics and high cell density capabilities. E. coli can grow quickly with doubling times of approximately 20 minutes in rich growth media <Paper corpusId=\"52017139\" paperTitle=\"(Chen et al., 2018)\" isShortName></Paper>, allowing for complete production cycles\u2014from inoculation to cell harvest\u2014to be completed in just hours rather than days or weeks required for eukaryotic systems <Paper corpusId=\"31546198\" paperTitle=\"(Francis et al., 2010)\" isShortName></Paper> <Paper corpusId=\"221365459\" paperTitle=\"(Ma et al., 2020)\" isShortName></Paper>. This rapid growth translates directly to higher volumetric productivity and more efficient use of bioreactor capacity <Paper corpusId=\"276466073\" paperTitle=\"(Vallejo et al., 2004)\" isShortName></Paper>. Commonly, E. coli can reach 1-2 g dry cell weight per liter of liquid medium, corresponding to approximately 10^13 cells <Paper corpusId=\"52017139\" paperTitle=\"(Chen et al., 2018)\" isShortName></Paper>, which supports high product yields in relatively small-footprint facilities.\n\nThe exceptional protein expression capacity of E. coli represents another major economic advantage. These bacteria can accumulate recombinant proteins in amounts of up to 80% of their dry matter <Paper corpusId=\"198595007\" paperTitle=\"(Sobolewska-Ruta et al., 2019)\" isShortName></Paper> <Paper corpusId=\"7945842\" paperTitle=\"(Baeshen et al., 2015)\" isShortName></Paper>. This high-level expression, combined with higher production rates compared to eukaryotic systems, results in superior volumetric productivities that significantly impact the overall economics of manufacturing <Paper corpusId=\"276466073\" paperTitle=\"(Vallejo et al., 2004)\" isShortName></Paper>.\n\nCost benefits also extend to processing time and resources. Mammalian cell cultivation is characterized by long cultivation times and requirements for expensive bioreactors <Paper corpusId=\"276466073\" paperTitle=\"(Vallejo et al., 2004)\" isShortName></Paper>. In contrast, E. coli-based production is faster and more straightforward, with protein production routinely achieved in a single day <Paper corpusId=\"31546198\" paperTitle=\"(Francis et al., 2010)\" isShortName></Paper>. The overall simplicity of bacterial cultivation processes reduces capital expenditure and operational costs while increasing production capacity <Paper corpusId=\"27151161\" paperTitle=\"(Lundstrom, 2007)\" isShortName></Paper>.\n\nThese economic advantages are reflected in the widespread industrial adoption of E. coli for commercial protein production. Approximately 29-40% of biopharmaceutical products approved between 2010 and 2014 were produced using E. coli <Paper corpusId=\"18974150\" paperTitle=\"(Marschall et al., 2016)\" isShortName></Paper> <Paper corpusId=\"4563831\" paperTitle=\"(Kopp et al., 2017)\" isShortName></Paper>. The system is particularly economical for non-glycosylated proteins, where the benefits of bacterial expression can be fully leveraged without concerns about post-translational modifications <Paper corpusId=\"198595007\" paperTitle=\"(Sobolewska-Ruta et al., 2019)\" isShortName></Paper> <Paper corpusId=\"221365459\" paperTitle=\"(Ma et al., 2020)\" isShortName></Paper>.\n\nWhen directly compared to alternative expression hosts, E. coli consistently demonstrates superior economics. Mammalian cell production systems, while capable of complex post-translational modifications, are typically 2-3 times more expensive and time-consuming <Paper corpusId=\"14322255\" paperTitle=\"(Blanco-Toribio et al., 2015)\" isShortName></Paper>. Yeast systems, while faster than mammalian cells, still present higher costs than E. coli and may suffer from genetic instability and clonal variation that can affect production consistency <Paper corpusId=\"57192905\" paperTitle=\"(Burdette et al., 2018)\" isShortName></Paper>. For proteins that do not require extensive post-translational modifications, E. coli provides the most economical option for industrial-scale production <Paper corpusId=\"237101690\" paperTitle=\"(Rigi et al., 2021)\" isShortName></Paper>.", "citations": [{"id": "(Casteleijn et al., 2025)", "paper": {"corpus_id": 275819850, "title": "Beyond In Vivo, Pharmaceutical Molecule Production in Cell-Free Systems and the Use of Noncanonical Amino Acids Therein", "year": 2025, "venue": "Chemical Reviews", "authors": [{"name": "Marco G Casteleijn", "authorId": "2341709622"}, {"name": "Ulrike Abendroth", "authorId": "2341708261"}, {"name": "Anne Zemella", "authorId": "4645161"}, {"name": "R. Walter", "authorId": "51105423"}, {"name": "Rashmi Rashmi", "authorId": "2341713643"}, {"name": "Rainer Haag", "authorId": "2341714868"}, {"name": "S. Kubick", "authorId": "5649709"}], "n_citations": 3}, "snippets": ["Another advantage is the culture conditions, which at large scale can be significant, since E. coli can be cultivated on relatively cheaply defined media (e.g., glucose, ammonia phosphate and some minerals) and strategies for low-cost production have been developed."], "score": 0.7998046875}, {"id": "(Chen et al., 2018)", "paper": {"corpus_id": 52017139, "title": "Genome-Wide Quantification of the Effect of Gene Overexpression on Escherichia coli Growth", "year": 2018, "venue": "Genes", "authors": [{"name": "Hao Chen", "authorId": "2149051625"}, {"name": "Suryawanshi Venkat Shivaji", "authorId": "14256725"}, {"name": "Jessica L Wilson", "authorId": "2115545597"}, {"name": "P. McGuire", "authorId": "40952720"}, {"name": "Abigail L Chang", "authorId": "51205479"}, {"name": "Qinglei Gan", "authorId": "3960574"}, {"name": "Chenguang Fan", "authorId": "6259156"}], "n_citations": 13}, "snippets": ["In both basic research and drug production, Escherichia coli is one of the most widely-used hosts to express recombinant proteins due to a number of advantages. First, it grows quickly, with a doubling time of about 20 min in rich growth media [2], which means the total time of expressing target proteins, from inoculation to cell harvest, is only a few hours in most circumstances. Second, it readily reaches a high cell density for good protein yields. Commonly, 1 to 2 g dry cell weight or 10\u00b9\u00b3 cells could be obtained from 1 L of liquid Lysogeny broth (LB) medium [2]. Third, it is cheap and easy to make growth media for E. coli such as the LB medium and the Terrific Broth (TB) medium. Fourth, the genetics of E. coli is well known, and it is convenient to remove certain genes from the genome for different purposes [3]. Fifth, it is easy to introduce heterologous genes into E. coli by plasmid transformation. Last but not least, a large number of vectors, fusion tags, and mutant strains have been developed for optimal expression of target proteins in E. coli."], "score": 0.72705078125}, {"id": "(Francis et al., 2010)", "paper": {"corpus_id": 31546198, "title": "Strategies to Optimize Protein Expression in E. coli", "year": 2010, "venue": "Current Protocols in Protein Science", "authors": [{"name": "D. Francis", "authorId": "6257099"}, {"name": "R. Page", "authorId": "3495828"}], "n_citations": 235}, "snippets": ["In spite of the development of multiple nonbacterial recombinant expression systems over the last three decades (yeast, baculovirus, mammalian cell, cell free systems; see Table 5.24.1), Escherichia coli is still the preferred host for recombinant protein expression (Yin et al., 2007). The rationale is clear: E. coli is easy to genetically manipulate, it is inexpensive to culture, and expression is fast, with proteins routinely produced in one day. Moreover, protocols for isotope-labeling for NMR spectroscopy and selenomethionine incorporation for X-ray crystallography are well established, making it highly suitable for structural studies. Thus, E. coli has multiple, significant benefits over other expression systems including cost, ease-of-use, and scale."], "score": 0.7900390625}, {"id": "(Ma et al., 2020)", "paper": {"corpus_id": 221365459, "title": "Strategies for Optimizing the Production of Proteins and Peptides with Multiple Disulfide Bonds", "year": 2020, "venue": "Antibiotics", "authors": [{"name": "Yunqi Ma", "authorId": "1914606211"}, {"name": "Chang-Joo Lee", "authorId": "2155591380"}, {"name": "Jang-Su Park", "authorId": "50001335"}], "n_citations": 39}, "snippets": ["E. coli expression systems are often used to produce exogenous protein on laboratory and industrial scales owing to the low cost, speed, and simplicity of cultivation [22]", "The advantages include rapid growth, fast expression, ease of cultivation, and high product yields (Zorko et al., 2009)(Zhu et al., 1999)(Zhou et al., 2009). It is used to manufacture large quantities of commercialized proteins. This method is particularly outstanding for the functional expression of non-glycosylated proteins", "The bacterium offers the least costly, simplest, and fastest method for protein production."], "score": 0.72412109375}, {"id": "(Vallejo et al., 2004)", "paper": {"corpus_id": 276466073, "title": "Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins", "year": 2004, "venue": "Microbial Cell Factories", "authors": [{"name": "L. F. Vallejo", "authorId": "40077396"}, {"name": "Ursula Rinas", "authorId": "2249734512"}], "n_citations": 3}, "snippets": ["Recombinant protein production in mammalian cells yields a biologically active protein with all the required posttranslational modifications. However, mammalian cell cultivation is characterized by low volumetric yields of the recombinant protein, long cultivation times and requirements for expensive bioreactors and medium components. All these points have a great impact on the production costs. On the other hand, bacterial cultivation processes are based on inexpensive media in which fast growth and high cell concentrations can be obtained. These high cell concentrations combined with higher production rates of the bacterial expression system result in higher volumetric productivities."], "score": 0.74560546875}, {"id": "(Sobolewska-Ruta et al., 2019)", "paper": {"corpus_id": 198595007, "title": "Cell Banks Preparation In Biopharmaceuticals Production", "year": 2019, "venue": "Advances in microbiology", "authors": [{"name": "Agnieszka Sobolewska-Ruta", "authorId": "1405189469"}, {"name": "P. Zaleski", "authorId": "5447587"}], "n_citations": 1}, "snippets": ["The use of bacteria is cost-effective due to low production costs, easy manipulation in the genome, fast growth rate and the possibility of using many molecular methods enabling to work with them at the cellular and molecular level. Bacteria are ideal for the production of low molecular weight proteins that do not require post-translational modifications [37].\n\nBacteria of the species E. coli strains are the most frequently the microbes of choice used for a large-scale production of proteins due to the well-known genome sequence, the best-defined transcription and translation system, the large selection of promoters described, the ease of genetic manipulation and the well-known metabolic and regulation pathways (Gopal et al., 2013)[36]", "Moreover, E. coli can accumulate recombinant proteins in an amount of up to 80% of its dry matter, and is characterized by the ability to survive in various environmental conditions [15]. These bacteria multiply quickly on relatively inexpensive substrates, and the large-scale recombinant protein synthesis process in bioreactors has been well studies and described [59]."], "score": 0.85107421875}, {"id": "(Baeshen et al., 2015)", "paper": {"corpus_id": 7945842, "title": "Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.", "year": 2015, "venue": "Journal of Microbiology and Biotechnology", "authors": [{"name": "M. Baeshen", "authorId": "5192370"}, {"name": "A. Al-hejin", "authorId": "9760654"}, {"name": "R. Bora", "authorId": "3970322"}, {"name": "Mohamed M M Ahmed", "authorId": "122517033"}, {"name": "H. Ramadan", "authorId": "31915002"}, {"name": "K. Saini", "authorId": "34967342"}, {"name": "N. Baeshen", "authorId": "2766125"}, {"name": "E. Redwan", "authorId": "2361015866"}], "n_citations": 264}, "snippets": ["Escherichia coli is the most preferred microorganism to express heterologous proteins for therapeutic use, as around 30% of the approved therapeutic proteins are currently being produced using it as a host. Owing to its rapid growth, high yield of the product, cost-effectiveness, and easy scale-up process, E. coli is an expression host of choice in the biotechnology industry for large-scale production of proteins, particularly non-glycosylated proteins, for therapeutic use. The availability of various E. coli expression vectors and strains, relatively easy protein folding mechanisms, and bioprocess technologies, makes it very attractive for industrial applications. However, the codon usage in E. coli and the absence of post-translational modifications, such as glycosylation, phosphorylation, and proteolytic processing, limit its use for the production of slightly complex recombinant biopharmaceuticals. Several new technological advancements in the E. coli expression system to meet the biotechnology industry requirements have been made, such as novel engineered strains, genetically modifying E. coli to possess capability to glycosylate heterologous proteins and express complex proteins, including full-length glycosylated antibodies. This review summarizes the recent advancements that may further expand the use of the E. coli expression system to produce more complex and also glycosylated proteins for therapeutic use in the future."], "score": 0.0}, {"id": "(Lundstrom, 2007)", "paper": {"corpus_id": 27151161, "title": "Structural Genomics", "year": 2007, "venue": "Systems Biology", "authors": [{"name": "K. Lundstrom", "authorId": "2422956"}], "n_citations": 4}, "snippets": ["The obvious advantage of prokaryotic expression is the ease of application and low production costs even at large scale level."], "score": 0.85546875}, {"id": "(Marschall et al., 2016)", "paper": {"corpus_id": 18974150, "title": "Tunable recombinant protein expression in E. coli: enabler for continuous processing?", "year": 2016, "venue": "Applied Microbiology and Biotechnology", "authors": [{"name": "Lukas Marschall", "authorId": "49334253"}, {"name": "P. Sagmeister", "authorId": "3060941"}, {"name": "C. Herwig", "authorId": "2349044"}], "n_citations": 35}, "snippets": ["E. coli emerged as the primary production workhorse for the biotechnological production of primary and secondary metabolites as well as recombinant proteins. This is reflected by the fact that 29 % of all biopharmaceutical products approved as biopharmaceuticals between 2010 and July 2014 are produced in E. coli (Walsh, 2000)", "researchers today have access to a broad spectrum of genetic tools and cultivation techniques, enabling simple and predictable genetic manipulation and cultivation on inexpensive media to high cell densities."], "score": 0.79052734375}, {"id": "(Kopp et al., 2017)", "paper": {"corpus_id": 4563831, "title": "Impact of Glycerol as Carbon Source onto Specific Sugar and Inducer Uptake Rates and Inclusion Body Productivity in E. coli BL21(DE3)", "year": 2017, "venue": "Bioengineering", "authors": [{"name": "J. Kopp", "authorId": "50614398"}, {"name": "C. Slouka", "authorId": "48293028"}, {"name": "Sophia Ulonska", "authorId": "4848500"}, {"name": "J. Kager", "authorId": "49596747"}, {"name": "J. Fricke", "authorId": "153513122"}, {"name": "O. Spadiut", "authorId": "3656797"}, {"name": "C. Herwig", "authorId": "2349044"}], "n_citations": 86}, "snippets": ["The Gram-negative bacterium E. coli is the host of choice for a multitude of used recombinant proteins. Generally, cultivation is easy, media are cheap, and a high product titer can be obtained.\n\nThe Gram-negative bacterium E. coli is the expression host of choice for the production of 30% to 40% of recombinant drugs in industry [1,2]. As E. coli shows very fast replication rates [3,4] on comparatively cheap media [5], the benefits often outweigh the numerous purification steps [1,6] and the missing glycosylation pattern [1,7]8]."], "score": 0.7451171875}, {"id": "(Blanco-Toribio et al., 2015)", "paper": {"corpus_id": 14322255, "title": "Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies", "year": 2015, "venue": "AMB Express", "authors": [{"name": "Ana Blanco-Toribio", "authorId": "1401238431"}, {"name": "Ana Alvarez-Cienfuegos", "authorId": "1398825836"}, {"name": "N. Sainz-Pastor", "authorId": "1401277010"}, {"name": "N. Merino", "authorId": "34907062"}, {"name": "M. Compte", "authorId": "144233748"}, {"name": "L. Sanz", "authorId": "145075472"}, {"name": "F. Blanco", "authorId": "143900481"}, {"name": "L. \u00c1lvarez-Vallina", "authorId": "1398825827"}], "n_citations": 3}, "snippets": ["Recombinant antibodies are used with great success in many different diagnostic and therapeutic applications. A variety of protein expression systems are available, but nowadays almost all therapeutic antibodies are produced in mammalian cell lines due to their complex structure and glycosylation requirements. However, production of clinical-grade antibodies in mammalian cells is very expensive and time-consuming. On the other hand, Escherichia coli (E. coli) is known to be the simplest, fastest and most cost-effective recombinant expression system, which usually achieves higher protein yields than mammalian cells. Indeed, it is one of the most popular host in the industry for the expression of recombinant proteins."], "score": 0.84716796875}, {"id": "(Burdette et al., 2018)", "paper": {"corpus_id": 57192905, "title": "Developing Gram-negative bacteria for the secretion of heterologous proteins", "year": 2018, "venue": "Microbial Cell Factories", "authors": [{"name": "Lisa A Burdette", "authorId": "18959724"}, {"name": "S. Leach", "authorId": "117224423"}, {"name": "Han Teng Wong", "authorId": "15311232"}, {"name": "D. Tullman-Ercek", "authorId": "1398379700"}], "n_citations": 92}, "snippets": ["Bacterial hosts offer fast growth, relative genetic simplicity, and genetic stability [15]. Gram-negative bacteria are attractive hosts for recombinant protein production because they are fast growing, easy to manipulate, and genetically stable in large cultures. However, the utility of these microbes would expand if they also could secrete the product at commercial scales. Secretion of biotechnologically relevant proteins into the extracellular medium increases product purity from cell culture, decreases downstream processing requirements, and reduces overall cost", "Mammalian cells, however, are slow growing, expensive to culture, have large batch to batch variations, and can be difficult to genetically engineer (Kim et al., 2011)(Datar et al., 1993). Yeasts typically are faster growing but can suffer from genetic instability and clonal variation (Caunt et al., 1988)."], "score": 0.84716796875}, {"id": "(Rigi et al., 2021)", "paper": {"corpus_id": 237101690, "title": "Optimization of expression, purification and secretion of functional recombinant human growth hormone in Escherichia coli using modified staphylococcal protein a signal peptide", "year": 2021, "venue": "BMC Biotechnology", "authors": [{"name": "G. Rigi", "authorId": "5164152"}, {"name": "A. Rostami", "authorId": "153507527"}, {"name": "Habib Ghomi", "authorId": "2123359136"}, {"name": "G. Ahmadian", "authorId": "3630197"}, {"name": "V. S. Mirbagheri", "authorId": "2123359505"}, {"name": "M. Jeiranikhameneh", "authorId": "9647101"}, {"name": "M. Vahed", "authorId": "13654093"}, {"name": "Sahel Rahimi", "authorId": "2123359958"}], "n_citations": 9}, "snippets": ["The advantages of this system include fast growth, high cell density using simple and low cost growth medium, known genetic information, availability of a large number of expression vectors and availability of mutant host strains, simple transfer, easy control, possibility of mass production of recombinant proteins and thus cost-effectiveness. In the case of yeast and mammalian hosts, in most cases, protein production is much lower and more expensive than E. coli host is."], "score": 0.86572265625}], "table": null}, {"title": "Time and Productivity Factors", "tldr": "E. coli's rapid growth cycle with doubling times as short as 20 minutes enables significantly faster production timelines compared to eukaryotic hosts. This exceptional growth rate, combined with high protein expression levels reaching up to 80% of dry cell weight, creates substantial productivity advantages for industrial recombinant protein manufacturing. (20 sources)", "text": "\nE. coli's remarkable growth kinetics represent one of its most significant economic advantages for large-scale industrial protein production. With doubling times of approximately 20 minutes under optimal conditions, E. coli grows substantially faster than alternative expression hosts <Paper corpusId=\"268523497\" paperTitle=\"(Koppl et al., 2024)\" isShortName></Paper> <Paper corpusId=\"7945842\" paperTitle=\"(Baeshen et al., 2015)\" isShortName></Paper> <Paper corpusId=\"52017139\" paperTitle=\"(Chen et al., 2018)\" isShortName></Paper> <Paper corpusId=\"267852486\" paperTitle=\"(Khlebodarova et al., 2024)\" isShortName></Paper>. This rapid growth translates to extremely short production cycles, where the entire process from inoculation to cell harvest can be completed in just hours rather than days or weeks required for mammalian cell systems <Paper corpusId=\"14322255\" paperTitle=\"(Blanco-Toribio et al., 2015)\" isShortName></Paper> <Paper corpusId=\"256211480\" paperTitle=\"(Blanco-Toribio et al._1, 2015)\" isShortName></Paper> <Paper corpusId=\"52017139\" paperTitle=\"(Chen et al., 2018)\" isShortName></Paper>.\n\nThe combination of rapid growth and high cell density capabilities further enhances E. coli's productivity advantages. The bacterium readily achieves high cell densities, commonly reaching 1-2 g dry cell weight per liter of liquid medium, which corresponds to approximately 10^13 cells <Paper corpusId=\"52017139\" paperTitle=\"(Chen et al., 2018)\" isShortName></Paper>. This high biomass production, coupled with exceptional protein expression capacity, creates a powerful productivity multiplier effect. E. coli can accumulate recombinant proteins in amounts of up to 80% of its dry matter, significantly higher than what is achievable in eukaryotic systems <Paper corpusId=\"198595007\" paperTitle=\"(Sobolewska-Ruta et al., 2019)\" isShortName></Paper> <Paper corpusId=\"34726680\" paperTitle=\"(Adrio et al., 2014)\" isShortName></Paper>.\n\nThese combined productivity factors make E. coli particularly valuable for industrial applications where time efficiency directly impacts economic outcomes. The system is especially well-suited for manufacturing non-glycosylated proteins where the benefits of bacterial expression can be fully leveraged without concerns about post-translational modifications <Paper corpusId=\"221365459\" paperTitle=\"(Ma et al., 2020)\" isShortName></Paper> <Paper corpusId=\"272499344\" paperTitle=\"(Incir et al., 2024)\" isShortName></Paper>. Multiple studies have confirmed that E. coli typically achieves higher protein yields than mammalian cell systems while requiring significantly less production time <Paper corpusId=\"14322255\" paperTitle=\"(Blanco-Toribio et al., 2015)\" isShortName></Paper> <Paper corpusId=\"256211480\" paperTitle=\"(Blanco-Toribio et al._1, 2015)\" isShortName></Paper>.\n\nThe productivity advantages of E. coli are further enhanced by its extensive genetic characterization and the availability of optimized expression tools. Decades of research have resulted in well-defined transcription and translation systems, along with a wide selection of characterized promoters, making it straightforward to optimize expression conditions <Paper corpusId=\"198595007\" paperTitle=\"(Sobolewska-Ruta et al., 2019)\" isShortName></Paper> <Paper corpusId=\"7900849\" paperTitle=\"(Ferrer-Miralles et al., 2013)\" isShortName></Paper> <Paper corpusId=\"13702233\" paperTitle=\"(Drejer et al., 2018)\" isShortName></Paper>. These features enable rapid process development and strain optimization, further reducing the time from concept to production <Paper corpusId=\"266308172\" paperTitle=\"(Leandro et al., 2023)\" isShortName></Paper> <Paper corpusId=\"237336823\" paperTitle=\"(Kheirabadi et al., 2021)\" isShortName></Paper>.\n\nE. coli's productivity advantages are particularly evident when directly compared to alternative expression hosts. While mammalian cell lines require complex cultivation processes with production cycles often lasting weeks, E. coli-based systems can achieve comparable protein yields in days or even hours <Paper corpusId=\"14322255\" paperTitle=\"(Blanco-Toribio et al., 2015)\" isShortName></Paper> <Paper corpusId=\"256211480\" paperTitle=\"(Blanco-Toribio et al._1, 2015)\" isShortName></Paper>. This dramatic difference in production timelines translates to higher facility throughput, more efficient use of production capacity, and ultimately lower costs per unit of protein produced <Paper corpusId=\"15371278\" paperTitle=\"(Tagkopoulos, 2013)\" isShortName></Paper> <Paper corpusId=\"233674494\" paperTitle=\"(Iftikhar, 2021)\" isShortName></Paper> <Paper corpusId=\"7564064\" paperTitle=\"(Costa et al., 2014)\" isShortName></Paper>.\n\nIndustrial adoption rates confirm the productivity advantages of E. coli, with approximately 30% of approved therapeutic proteins being produced using this bacterial host <Paper corpusId=\"268523497\" paperTitle=\"(Koppl et al., 2024)\" isShortName></Paper> <Paper corpusId=\"7945842\" paperTitle=\"(Baeshen et al., 2015)\" isShortName></Paper>. Even with the advancement of alternative expression systems, E. coli remains competitive for many applications due to its unmatched combination of rapid growth, high expression levels, and process simplicity <Paper corpusId=\"255290846\" paperTitle=\"(Bartolo-Aguilar et al., 2022)\" isShortName></Paper> <Paper corpusId=\"206394618\" paperTitle=\"(Rosano et al., 2019)\" isShortName></Paper> <Paper corpusId=\"38109425\" paperTitle=\"(Amiri et al., 2018)\" isShortName></Paper>.", "citations": [{"id": "(Koppl et al., 2024)", "paper": {"corpus_id": 268523497, "title": "Modifications of the 5\u2019 region of the CASPONTM tag\u2019s mRNA further enhance soluble recombinant protein production in Escherichia coli", "year": 2024, "venue": "Microbial Cell Factories", "authors": [{"name": "C. K\u00f6ppl", "authorId": "11989956"}, {"name": "Wolfgang Buchinger", "authorId": "2292131527"}, {"name": "G. Striedner", "authorId": "3190875"}, {"name": "M. Cserjan\u2010Puschmann", "authorId": "1403473552"}], "n_citations": 5}, "snippets": ["Escherichia coli is one of the most commonly used host organisms for the production of biopharmaceuticals, as it allows for cost-efficient and fast recombinant protein expression. Today, about 30% of approved biopharmaceuticals are produced by E. coli, and despite the recent advance of other production systems such as mammalian cell culture, new product approvals, like Beovu\u00ae and Cablivi R in 2019, are constantly being granted, allowing E. coli to compete with both mammalian and non-mammalian hosts (McElwain et al., 2022)(Baeshen et al., 2015)."], "score": 0.8154296875}, {"id": "(Baeshen et al., 2015)", "paper": {"corpus_id": 7945842, "title": "Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.", "year": 2015, "venue": "Journal of Microbiology and Biotechnology", "authors": [{"name": "M. Baeshen", "authorId": "5192370"}, {"name": "A. Al-hejin", "authorId": "9760654"}, {"name": "R. Bora", "authorId": "3970322"}, {"name": "Mohamed M M Ahmed", "authorId": "122517033"}, {"name": "H. Ramadan", "authorId": "31915002"}, {"name": "K. Saini", "authorId": "34967342"}, {"name": "N. Baeshen", "authorId": "2766125"}, {"name": "E. Redwan", "authorId": "2361015866"}], "n_citations": 264}, "snippets": ["Escherichia coli is the most preferred microorganism to express heterologous proteins for therapeutic use, as around 30% of the approved therapeutic proteins are currently being produced using it as a host. Owing to its rapid growth, high yield of the product, cost-effectiveness, and easy scale-up process, E. coli is an expression host of choice in the biotechnology industry for large-scale production of proteins, particularly non-glycosylated proteins, for therapeutic use. The availability of various E. coli expression vectors and strains, relatively easy protein folding mechanisms, and bioprocess technologies, makes it very attractive for industrial applications. However, the codon usage in E. coli and the absence of post-translational modifications, such as glycosylation, phosphorylation, and proteolytic processing, limit its use for the production of slightly complex recombinant biopharmaceuticals. Several new technological advancements in the E. coli expression system to meet the biotechnology industry requirements have been made, such as novel engineered strains, genetically modifying E. coli to possess capability to glycosylate heterologous proteins and express complex proteins, including full-length glycosylated antibodies. This review summarizes the recent advancements that may further expand the use of the E. coli expression system to produce more complex and also glycosylated proteins for therapeutic use in the future."], "score": 0.0}, {"id": "(Chen et al., 2018)", "paper": {"corpus_id": 52017139, "title": "Genome-Wide Quantification of the Effect of Gene Overexpression on Escherichia coli Growth", "year": 2018, "venue": "Genes", "authors": [{"name": "Hao Chen", "authorId": "2149051625"}, {"name": "Suryawanshi Venkat Shivaji", "authorId": "14256725"}, {"name": "Jessica L Wilson", "authorId": "2115545597"}, {"name": "P. McGuire", "authorId": "40952720"}, {"name": "Abigail L Chang", "authorId": "51205479"}, {"name": "Qinglei Gan", "authorId": "3960574"}, {"name": "Chenguang Fan", "authorId": "6259156"}], "n_citations": 13}, "snippets": ["In both basic research and drug production, Escherichia coli is one of the most widely-used hosts to express recombinant proteins due to a number of advantages. First, it grows quickly, with a doubling time of about 20 min in rich growth media [2], which means the total time of expressing target proteins, from inoculation to cell harvest, is only a few hours in most circumstances. Second, it readily reaches a high cell density for good protein yields. Commonly, 1 to 2 g dry cell weight or 10\u00b9\u00b3 cells could be obtained from 1 L of liquid Lysogeny broth (LB) medium [2]. Third, it is cheap and easy to make growth media for E. coli such as the LB medium and the Terrific Broth (TB) medium. Fourth, the genetics of E. coli is well known, and it is convenient to remove certain genes from the genome for different purposes [3]. Fifth, it is easy to introduce heterologous genes into E. coli by plasmid transformation. Last but not least, a large number of vectors, fusion tags, and mutant strains have been developed for optimal expression of target proteins in E. coli."], "score": 0.72705078125}, {"id": "(Khlebodarova et al., 2024)", "paper": {"corpus_id": 267852486, "title": "Komagataella phaffii as a Platform for Heterologous Expression of Enzymes Used for Industry", "year": 2024, "venue": "Microorganisms", "authors": [{"name": "T. M. Khlebodarova", "authorId": "2274845306"}, {"name": "Natalia V Bogacheva", "authorId": "2285777312"}, {"name": "A. V. Zadorozhny", "authorId": "2181076146"}, {"name": "A. V. Bryanskaya", "authorId": "2181077470"}, {"name": "A. Vasilieva", "authorId": "2181076574"}, {"name": "Danil O Chesnokov", "authorId": "2181076670"}, {"name": "Elena I Pavlova", "authorId": "2181072805"}, {"name": "Sergey E. Peltek", "authorId": "2267185330"}], "n_citations": 10}, "snippets": ["In the 1980s, Escherichia coli was the preferred host for heterologous protein expression owing to its capacity for rapid growth (cell doubling time: 20 min) in complex media; wellstudied genetics, physiology, and metabolism; rapid and direct transformation with foreign DNA; and easily scalable fermentation (Pope et al., 1996)(S\u00f8rensen et al., 2005)(Sezonov et al., 2007)[4](Bahreini et al., 2014)."], "score": 0.7216796875}, {"id": "(Blanco-Toribio et al., 2015)", "paper": {"corpus_id": 14322255, "title": "Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies", "year": 2015, "venue": "AMB Express", "authors": [{"name": "Ana Blanco-Toribio", "authorId": "1401238431"}, {"name": "Ana Alvarez-Cienfuegos", "authorId": "1398825836"}, {"name": "N. Sainz-Pastor", "authorId": "1401277010"}, {"name": "N. Merino", "authorId": "34907062"}, {"name": "M. Compte", "authorId": "144233748"}, {"name": "L. Sanz", "authorId": "145075472"}, {"name": "F. Blanco", "authorId": "143900481"}, {"name": "L. \u00c1lvarez-Vallina", "authorId": "1398825827"}], "n_citations": 3}, "snippets": ["Recombinant antibodies are used with great success in many different diagnostic and therapeutic applications. A variety of protein expression systems are available, but nowadays almost all therapeutic antibodies are produced in mammalian cell lines due to their complex structure and glycosylation requirements. However, production of clinical-grade antibodies in mammalian cells is very expensive and time-consuming. On the other hand, Escherichia coli (E. coli) is known to be the simplest, fastest and most cost-effective recombinant expression system, which usually achieves higher protein yields than mammalian cells. Indeed, it is one of the most popular host in the industry for the expression of recombinant proteins."], "score": 0.84716796875}, {"id": "(Blanco-Toribio et al._1, 2015)", "paper": {"corpus_id": 256211480, "title": "Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies", "year": 2015, "venue": "AMB Express", "authors": [{"name": "Ana Blanco-Toribio", "authorId": "1401238431"}, {"name": "Ana Alvarez-Cienfuegos", "authorId": "1398825836"}, {"name": "N. Sainz-Pastor", "authorId": "1401277010"}, {"name": "N. Merino", "authorId": "34907062"}, {"name": "M. Compte", "authorId": "144233748"}, {"name": "L. Sanz", "authorId": "145075472"}, {"name": "F. Blanco", "authorId": "143900481"}, {"name": "L. \u00c1lvarez-Vallina", "authorId": "1398825827"}], "n_citations": 0}, "snippets": ["Recombinant antibodies are used with great success in many different diagnostic and therapeutic applications. A variety of protein expression systems are available, but nowadays almost all therapeutic antibodies are produced in mammalian cell lines due to their complex structure and glycosylation requirements. However, production of clinical-grade antibodies in mammalian cells is very expensive and time-consuming. On the other hand, Escherichia coli (E. coli) is known to be the simplest, fastest and most cost-effective recombinant expression system, which usually achieves higher protein yields than mammalian cells. Indeed, it is one of the most popular host in the industry for the expression of recombinant proteins."], "score": 0.84716796875}, {"id": "(Sobolewska-Ruta et al., 2019)", "paper": {"corpus_id": 198595007, "title": "Cell Banks Preparation In Biopharmaceuticals Production", "year": 2019, "venue": "Advances in microbiology", "authors": [{"name": "Agnieszka Sobolewska-Ruta", "authorId": "1405189469"}, {"name": "P. Zaleski", "authorId": "5447587"}], "n_citations": 1}, "snippets": ["The use of bacteria is cost-effective due to low production costs, easy manipulation in the genome, fast growth rate and the possibility of using many molecular methods enabling to work with them at the cellular and molecular level. Bacteria are ideal for the production of low molecular weight proteins that do not require post-translational modifications [37].\n\nBacteria of the species E. coli strains are the most frequently the microbes of choice used for a large-scale production of proteins due to the well-known genome sequence, the best-defined transcription and translation system, the large selection of promoters described, the ease of genetic manipulation and the well-known metabolic and regulation pathways (Gopal et al., 2013)[36]", "Moreover, E. coli can accumulate recombinant proteins in an amount of up to 80% of its dry matter, and is characterized by the ability to survive in various environmental conditions [15]. These bacteria multiply quickly on relatively inexpensive substrates, and the large-scale recombinant protein synthesis process in bioreactors has been well studies and described [59]."], "score": 0.85107421875}, {"id": "(Adrio et al., 2014)", "paper": {"corpus_id": 34726680, "title": "Microbial Enzymes: Tools for Biotechnological Processes", "year": 2014, "venue": "Biomolecules", "authors": [{"name": "J. Adrio", "authorId": "37903974"}, {"name": "A. Demain", "authorId": "3631952"}], "n_citations": 635}, "snippets": ["E. coli has been extensively used as a recombinant host for many reasons including (i) ease of quickly and precisely modifying the genome; (ii) rapid growth to high cell densities; (iii) ease of culture in cheap media; and (iv) ease of reduction of protease activity. E. coli can accumulate heterologous proteins up to 50% of its dry cell weight [88]."], "score": 0.765625}, {"id": "(Ma et al., 2020)", "paper": {"corpus_id": 221365459, "title": "Strategies for Optimizing the Production of Proteins and Peptides with Multiple Disulfide Bonds", "year": 2020, "venue": "Antibiotics", "authors": [{"name": "Yunqi Ma", "authorId": "1914606211"}, {"name": "Chang-Joo Lee", "authorId": "2155591380"}, {"name": "Jang-Su Park", "authorId": "50001335"}], "n_citations": 39}, "snippets": ["E. coli expression systems are often used to produce exogenous protein on laboratory and industrial scales owing to the low cost, speed, and simplicity of cultivation [22]", "The advantages include rapid growth, fast expression, ease of cultivation, and high product yields (Zorko et al., 2009)(Zhu et al., 1999)(Zhou et al., 2009). It is used to manufacture large quantities of commercialized proteins. This method is particularly outstanding for the functional expression of non-glycosylated proteins", "The bacterium offers the least costly, simplest, and fastest method for protein production."], "score": 0.72412109375}, {"id": "(Incir et al., 2024)", "paper": {"corpus_id": 272499344, "title": "Escherichia coli in the production of biopharmaceuticals", "year": 2024, "venue": "Biotechnology and applied biochemistry", "authors": [{"name": "\u0130brahim \u0130ncir", "authorId": "2135873506"}, {"name": "\u00d6zlem Kaplan", "authorId": "2099005501"}], "n_citations": 5}, "snippets": ["E. coli is favored for large-scale manufacturing due to its quick growth, inexpensive nutritional needs, simplicity in scaling up, and capacity to produce high-yield, highquality pharmaceuticals."], "score": 0.7666015625}, {"id": "(Ferrer-Miralles et al., 2013)", "paper": {"corpus_id": 7900849, "title": "Bacterial cell factories for recombinant protein production; expanding the catalogue", "year": 2013, "venue": "Microbial Cell Factories", "authors": [{"name": "N. Ferrer-Miralles", "authorId": "1398661962"}, {"name": "A. Villaverde", "authorId": "5106321"}], "n_citations": 96}, "snippets": ["Escherichia coli has been the pioneering host for recombinant protein production, since the original recombinant DNA procedures were developed using its genetic material and infecting bacteriophages. As a consequence, and because of the accumulated know-how on E. coli genetics and physiology and the increasing number of tools for genetic engineering adapted to this bacterium, E. coli is the preferred host when attempting the production of a new protein. Also, it is still the first choice for protein production at laboratory and industrial scales for an important number of proteins, being fast growth and simple culture procedures critical issues."], "score": 0.794921875}, {"id": "(Drejer et al., 2018)", "paper": {"corpus_id": 13702233, "title": "Genetic Tools and Techniques for Recombinant Expression in Thermophilic Bacillaceae", "year": 2018, "venue": "Microorganisms", "authors": [{"name": "E. B. Drejer", "authorId": "51069447"}, {"name": "Sigrid Hakv\u00e5g", "authorId": "6365937"}, {"name": "Marta Irla", "authorId": "14589143"}, {"name": "T. Brautaset", "authorId": "4883160"}], "n_citations": 40}, "snippets": ["E. coli is in many cases the most used host due to several advantages, including an extensively developed genetic tool box, well-known genetics and physiology, low-cost media, and rapid protein production in a short fermentation period (Zhou et al., 2017)."], "score": 0.7568359375}, {"id": "(Leandro et al., 2023)", "paper": {"corpus_id": 266308172, "title": "Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes", "year": 2023, "venue": "Toxins", "authors": [{"name": "L. di Leandro", "authorId": "4872494"}, {"name": "Martina Colasante", "authorId": "2211162453"}, {"name": "G. Pitari", "authorId": "49801786"}, {"name": "R. Ippoliti", "authorId": "2577428"}], "n_citations": 1}, "snippets": ["E. coli can grow rapidly and produce high-density cultures using quite inexpensive culture media, allowing, in many cases, for high yields of the protein of interest", "Because of its ability to rapidly grow in a high-density environment in a low-cost medium, its well-defined genetic traits, and the multiplicity of cloning vectors and mutant host strains, E. coli offers an efficient and cost-effective method for the rapid and high-yield production of proteins."], "score": 0.7646484375}, {"id": "(Kheirabadi et al., 2021)", "paper": {"corpus_id": 237336823, "title": "Cloning, Expression, and Purification of Recombinant Mouse Interferon-\u03b3", "year": 2021, "venue": "Research in Molecular Medicine", "authors": [{"name": "Seyedeh Elham Badiee Kheirabadi", "authorId": "2124756425"}, {"name": "Kazem Mashayekhi", "authorId": "39713298"}, {"name": "M. Moghadam", "authorId": "37476979"}, {"name": "M. Mousavi", "authorId": "46188576"}, {"name": "M. Sankian", "authorId": "3598806"}], "n_citations": 0}, "snippets": ["Because of its short life cycle, easy genetic manipulation, and simple culture conditions, E. coli is a preferable host to produce many recombinant proteins (Abdi et al., 2019)(Maleki et al., 2020)", "Although all bacteria could be used for recombinant protein technologies, E. coli is still the preferable host for the industrial production of recombinant proteins (Terpe, 2006)."], "score": 0.71533203125}, {"id": "(Tagkopoulos, 2013)", "paper": {"corpus_id": 15371278, "title": "Microbial factories under control", "year": 2013, "venue": "Bioengineered", "authors": [{"name": "I. Tagkopoulos", "authorId": "47371626"}], "n_citations": 5}, "snippets": ["E. coli is arguably one of the most widely used hosts for recombinant protein production since it can achieve high yields, it is fast and inexpensive to grow and it can be easily modified."], "score": 0.72509765625}, {"id": "(Iftikhar, 2021)", "paper": {"corpus_id": 233674494, "title": "Expression of Foreign Proteins in\u00a0Escherichia coli", "year": 2021, "venue": "", "authors": [{"name": "A. Iftikhar", "authorId": "8080001"}], "n_citations": 0}, "snippets": ["E. coli remains the dominant host for the production of recombinant proteins because it is inexpensive and cost-effective for mass production of recombinant proteins. E. coli has a fast growth rate with early protein expression and high protein yield, which makes it preferable over other expression systems. Because of the better understanding of E. coli mode of transcription and translation, it is easier to manipulate its genome to optimize protein expression."], "score": 0.80029296875}, {"id": "(Costa et al., 2014)", "paper": {"corpus_id": 7564064, "title": "Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system", "year": 2014, "venue": "Frontiers in Microbiology", "authors": [{"name": "S. Costa", "authorId": "30300329"}, {"name": "A. Almeida", "authorId": "144979049"}, {"name": "A. Castro", "authorId": "2107379880"}, {"name": "L. Domingues", "authorId": "3642789"}], "n_citations": 400}, "snippets": ["Escherichia coli remains the dominant host for producing recombinant proteins, owing to its advantageous fast and inexpensive, and high yield protein production, together with the well-characterized genetics and variety of available molecular tools (Demain et al., 2009)."], "score": 0.77294921875}, {"id": "(Bartolo-Aguilar et al., 2022)", "paper": {"corpus_id": 255290846, "title": "The potential of cold-shock promoters for the expression of recombinant proteins in microbes and mammalian cells", "year": 2022, "venue": "Journal of Genetic Engineering and Biotechnology", "authors": [{"name": "Y. Bartolo-Aguilar", "authorId": "102122715"}, {"name": "C. Ch\u00e1vez-Cabrera", "authorId": "1411694345"}, {"name": "L. Flores-Cotera", "authorId": "102196991"}, {"name": "J. Badillo-Corona", "authorId": "1398910333"}, {"name": "Carmen Oliver-Salvador", "authorId": "1422414490"}, {"name": "R. Marsch", "authorId": "6690939"}], "n_citations": 11}, "snippets": ["Escherichia coli has been a widely used bacterium for the expression of recombinant proteins, mainly due to its multiple advantages such as fast growth, high yield, low production costs, easy genetic manipulation, and availability of multiple molecular tools (Costa et al., 2014)(Rosano et al., 2019)[3]."], "score": 0.68994140625}, {"id": "(Rosano et al., 2019)", "paper": {"corpus_id": 206394618, "title": "New tools for recombinant protein production in Escherichia coli: A 5\u2010year update", "year": 2019, "venue": "Protein Science", "authors": [{"name": "Germ\u00e1n L. Rosano", "authorId": "40548489"}, {"name": "Enrique S Morales", "authorId": "46990100"}, {"name": "E. Ceccarelli", "authorId": "40501475"}], "n_citations": 262}, "snippets": ["The production of proteins in sufficient amounts is key for their study or use as biotherapeutic agents. Escherichia coli is the host of choice for recombinant protein production given its fast growth, easy manipulation, and cost\u2010effectiveness. As such, its protein production capabilities are continuously being improved. Also, the associated tools (such as plasmids and cultivation conditions) are subject of ongoing research to optimize product yield. In this work, we review the latest advances in recombinant protein production in E. coli."], "score": 0.0}, {"id": "(Amiri et al., 2018)", "paper": {"corpus_id": 38109425, "title": "Expression Optimization of Anti-CD22 scFv-Apoptin Fusion Protein Using Experimental Design Methodology", "year": 2018, "venue": "Iranian Biomedical Journal", "authors": [{"name": "S. Amiri", "authorId": "48873031"}, {"name": "N. Zarei", "authorId": "5003764"}, {"name": "S. Enayati", "authorId": "4199037"}, {"name": "M. Azizi", "authorId": "47045956"}, {"name": "V. Khalaj", "authorId": "3593984"}, {"name": "S. Shahhosseini", "authorId": "4870660"}], "n_citations": 6}, "snippets": ["The advantages of using E. coli as a bacterial expression system include the rapid growth rate to high cell density, inexpensive production substrate, and easy genetic manipulation and transformation [4]5]."], "score": 0.75244140625}], "table": null}, {"title": "Genetic Manipulation and Scale-up Economics", "tldr": "E. coli's well-characterized genome and extensive genetic toolkit enable fast, precise, and cost-effective genetic manipulations compared to alternative hosts. These genetic advantages, combined with efficient scale-up properties, significantly reduce development timelines and manufacturing costs for industrial protein production. (16 sources)", "text": "\nE. coli's economic advantages for large-scale recombinant protein production are significantly enhanced by its exceptional genetic accessibility and manipulation capabilities. The bacterium possesses a well-characterized genome and genetic map, making it substantially easier to precisely modify than alternative expression hosts <Paper corpusId=\"238699382\" paperTitle=\"(Gupta et al., 2021)\" isShortName></Paper> <Paper corpusId=\"258398053\" paperTitle=\"(Pouresmaeil et al., 2023)\" isShortName></Paper>. This genetic tractability allows researchers to rapidly and accurately modify the E. coli genome to optimize protein expression parameters <Paper corpusId=\"233674494\" paperTitle=\"(Iftikhar, 2021)\" isShortName></Paper> <Paper corpusId=\"270191517\" paperTitle=\"(Zhu et al., 2024)\" isShortName></Paper>.\n\nThe bacterial host's genetic advantages are bolstered by an extensively developed genetic toolbox that has evolved over decades of research. This includes a wide variety of expression vectors, engineered host strains, and well-defined transcription and translation systems <Paper corpusId=\"13702233\" paperTitle=\"(Drejer et al., 2018)\" isShortName></Paper> <Paper corpusId=\"196660066\" paperTitle=\"(Al-hejin et al., 2019)\" isShortName></Paper>. The availability of these genetic tools facilitates straightforward transformation procedures that are highly efficient and cost-effective compared to the more complex genetic manipulation requirements of multicellular organisms <Paper corpusId=\"258398053\" paperTitle=\"(Pouresmaeil et al., 2023)\" isShortName></Paper> <Paper corpusId=\"38109425\" paperTitle=\"(Amiri et al., 2018)\" isShortName></Paper> <Paper corpusId=\"1585460\" paperTitle=\"(Rosano et al., 2014)\" isShortName></Paper>.\n\nFrom an industrial scale-up perspective, E. coli offers several economic advantages that directly impact manufacturing costs. The system's ability to rapidly progress from laboratory-scale experiments to large-scale manufacturing represents a significant economic benefit <Paper corpusId=\"370734\" paperTitle=\"(Gao et al., 2012)\" isShortName></Paper>. E. coli can be efficiently grown to high cell densities in inexpensive media, with the potential to accumulate heterologous proteins up to 50% of its dry cell weight <Paper corpusId=\"34726680\" paperTitle=\"(Adrio et al., 2014)\" isShortName></Paper>. This exceptional protein expression capability, combined with the ease of scale-up, contributes to E. coli's status as the preferred host for industrial-scale protein production <Paper corpusId=\"237336823\" paperTitle=\"(Kheirabadi et al., 2021)\" isShortName></Paper> <Paper corpusId=\"199075971\" paperTitle=\"(Abdi et al., 2019)\" isShortName></Paper>.\n\nThe industrial importance of these combined genetic and scale-up advantages is reflected in E. coli's dominant position in commercial protein production. Approximately 30-40% of therapeutic proteins approved for clinical use are produced using E. coli <Paper corpusId=\"237677625\" paperTitle=\"(Mitchell et al., 2021)\" isShortName></Paper> <Paper corpusId=\"7945842\" paperTitle=\"(Baeshen et al., 2015)\" isShortName></Paper> <Paper corpusId=\"18974150\" paperTitle=\"(Marschall et al., 2016)\" isShortName></Paper>. This widespread industrial adoption demonstrates the economic viability of E. coli-based production systems, particularly for non-glycosylated proteins where the benefits of bacterial expression can be fully leveraged <Paper corpusId=\"7945842\" paperTitle=\"(Baeshen et al., 2015)\" isShortName></Paper>.\n\nDespite its many advantages, it's worth noting that E. coli production systems do face some economic challenges related to downstream processing. The presence of endogenously produced endotoxins and potential pathogens can make purification more complex and costly for certain applications, particularly those requiring clinical-grade materials <Paper corpusId=\"370734\" paperTitle=\"(Gao et al., 2012)\" isShortName></Paper>. However, for many industrial applications, the overall economic benefits of using E. coli\u2014including its low production costs, genetic tractability, and efficient scale-up properties\u2014continue to make it the most cost-effective choice among available expression systems <Paper corpusId=\"276480527\" paperTitle=\"(Chen et al., 2025)\" isShortName></Paper>.", "citations": [{"id": "(Gupta et al., 2021)", "paper": {"corpus_id": 238699382, "title": "Strategies for Enhancing Product Yield: Design of Experiments (DOE) for Escherichia coli Cultivation", "year": 2021, "venue": "Fermentation", "authors": [{"name": "P. Gupta", "authorId": "2119999520"}, {"name": "Jyotheeswara Edula", "authorId": "2127891"}], "n_citations": 2}, "snippets": ["The selection of host cells for industrial application has some technical difficulties despite the availability of many gene manipulations theoretically in various organisms. The availability of a genetic map, gene exchange system, useful vector and transformation procedures, and metabolic pathways leading from raw material to the desired product are essential criteria for selecting a suitable host strain. The most popular organisms used to date for the expression of the recombinant proteins are E. coli, Bacillus subtilis, Bacillus stearothermophillus, Streptomyces spp, Corynebacterium, Saccharomyces cerevisiae, Pichia pastoris, Hansenula polymorpha and various animal/plant cells. E. coli remains an important host system for the industrial protein production from cloned genes as one of the main applications of genetic engineering in biotechnology. Various efficient expression vector systems have been developed, and a variety of mutants are available as host strains for different purposes (Favre-Bulle et al., 1991)(Sabatie et al., 1991). Overexpression of a heterologous protein is possible in E. coli, making it suitable for industrial production."], "score": 0.72607421875}, {"id": "(Pouresmaeil et al., 2023)", "paper": {"corpus_id": 258398053, "title": "Factors involved in heterologous expression of proteins in E. coli host", "year": 2023, "venue": "Archives of Microbiology", "authors": [{"name": "Mahin Pouresmaeil", "authorId": "2208489512"}, {"name": "Shahnam Azizi-Dargahlou", "authorId": "2179061179"}], "n_citations": 50}, "snippets": ["The bacterial host is the most used expression system due to its simple expression method and low cost", "Easy manipulation of the genome of unicellular hosts such as bacteria is their main advantage over multicellular organisms. In addition, unlike multicellular organisms, the transformation of bacteria is simple, highly efficient, and cost-effective (Baneyx, 1999)."], "score": 0.74072265625}, {"id": "(Iftikhar, 2021)", "paper": {"corpus_id": 233674494, "title": "Expression of Foreign Proteins in\u00a0Escherichia coli", "year": 2021, "venue": "", "authors": [{"name": "A. Iftikhar", "authorId": "8080001"}], "n_citations": 0}, "snippets": ["E. coli remains the dominant host for the production of recombinant proteins because it is inexpensive and cost-effective for mass production of recombinant proteins. E. coli has a fast growth rate with early protein expression and high protein yield, which makes it preferable over other expression systems. Because of the better understanding of E. coli mode of transcription and translation, it is easier to manipulate its genome to optimize protein expression."], "score": 0.80029296875}, {"id": "(Zhu et al., 2024)", "paper": {"corpus_id": 270191517, "title": "A review of chimeric proteins/enzymes", "year": 2024, "venue": "BIO Web of Conferences", "authors": [{"name": "Jiakang Zhu", "authorId": "2304215554"}, {"name": "Song Han", "authorId": "2304296427"}, {"name": "Le Gao", "authorId": "2304296913"}], "n_citations": 0}, "snippets": ["Escherichia coli is one of the earliest and most widely used hosts for heterologous protein production.With its advantages of relatively simple operation, low cost and high success rate, Escherichia coli can be widely used in biotechnology to promote protein expression, especially for functional expression of non-glycosylated proteins.E. coli genome can be modified rapidly and accurately, promoter control is not difficult, plasmid copy number is easy to change, and it has better controllability."], "score": 0.7158203125}, {"id": "(Drejer et al., 2018)", "paper": {"corpus_id": 13702233, "title": "Genetic Tools and Techniques for Recombinant Expression in Thermophilic Bacillaceae", "year": 2018, "venue": "Microorganisms", "authors": [{"name": "E. B. Drejer", "authorId": "51069447"}, {"name": "Sigrid Hakv\u00e5g", "authorId": "6365937"}, {"name": "Marta Irla", "authorId": "14589143"}, {"name": "T. Brautaset", "authorId": "4883160"}], "n_citations": 40}, "snippets": ["E. coli is in many cases the most used host due to several advantages, including an extensively developed genetic tool box, well-known genetics and physiology, low-cost media, and rapid protein production in a short fermentation period (Zhou et al., 2017)."], "score": 0.7568359375}, {"id": "(Al-hejin et al., 2019)", "paper": {"corpus_id": 196660066, "title": "Plasmids for Optimizing Expression of Recombinant Proteins in E. coli", "year": 2019, "venue": "Plasmid", "authors": [{"name": "A. Al-hejin", "authorId": "9760654"}, {"name": "R. Bora", "authorId": "3970322"}, {"name": "Mohamed Ahmed", "authorId": "2299938259"}], "n_citations": 6}, "snippets": ["E. coli is a preferred expression system for production of heterologous proteins due to its well-characterized genetics, ease of genetic manipulation, availability of several plasmid vectors and engineered host strains, low manufacturing cost, high yield of recombinant proteins as compared to other expression systems including yeast, mammalian cell lines, transgenic plants and transgenic animals."], "score": 0.91259765625}, {"id": "(Amiri et al., 2018)", "paper": {"corpus_id": 38109425, "title": "Expression Optimization of Anti-CD22 scFv-Apoptin Fusion Protein Using Experimental Design Methodology", "year": 2018, "venue": "Iranian Biomedical Journal", "authors": [{"name": "S. Amiri", "authorId": "48873031"}, {"name": "N. Zarei", "authorId": "5003764"}, {"name": "S. Enayati", "authorId": "4199037"}, {"name": "M. Azizi", "authorId": "47045956"}, {"name": "V. Khalaj", "authorId": "3593984"}, {"name": "S. Shahhosseini", "authorId": "4870660"}], "n_citations": 6}, "snippets": ["The advantages of using E. coli as a bacterial expression system include the rapid growth rate to high cell density, inexpensive production substrate, and easy genetic manipulation and transformation [4]5]."], "score": 0.75244140625}, {"id": "(Rosano et al., 2014)", "paper": {"corpus_id": 1585460, "title": "Recombinant protein expression in Escherichia coli: advances and challenges", "year": 2014, "venue": "Frontiers in Microbiology", "authors": [{"name": "Germ\u00e1n L. Rosano", "authorId": "40548489"}, {"name": "E. Ceccarelli", "authorId": "40501475"}], "n_citations": 2165}, "snippets": ["Escherichia coli is one of the organisms of choice for the production of recombinant proteins. Its use as a cell factory is well-established and it has become the most popular expression platform. For this reason, there are many molecular tools and protocols at hand for the high-level production of heterologous proteins, such as a vast catalog of expression plasmids, a great number of engineered strains and many cultivation strategies. We review the different approaches for the synthesis of recombinant proteins in E. coli and discuss recent progress in this ever-growing field."], "score": 0.0}, {"id": "(Gao et al., 2012)", "paper": {"corpus_id": 370734, "title": "Stable Plastid Transformation for High-Level Recombinant Protein Expression: Promises and Challenges", "year": 2012, "venue": "Journal of Biomedicine and Biotechnology", "authors": [{"name": "Meili Gao", "authorId": "8066136"}, {"name": "Yongfei Li", "authorId": "2110480714"}, {"name": "X. Xue", "authorId": "4131861"}, {"name": "Xianfeng Wang", "authorId": "2108007804"}, {"name": "J. Long", "authorId": "4738004"}], "n_citations": 17}, "snippets": ["The cost of the resulting product, especially downstream processing or purification cost has been described as the following. (Mett et al., 2008) The generation of recombinant proteins in bacterial system is faster and easier and thus allows for the easy progression to large-scale manufacturing (Weisser et al., 2009). Currently, the most widely used recombinant protein production systems are bacterial systems. However, the limitation of the presence of endogenously produced endotoxins and pathogens in E. coli is difficult and, therefore, costly to remove from target preparations and creates additional complexities (Mett et al., 2008)."], "score": 0.77978515625}, {"id": "(Adrio et al., 2014)", "paper": {"corpus_id": 34726680, "title": "Microbial Enzymes: Tools for Biotechnological Processes", "year": 2014, "venue": "Biomolecules", "authors": [{"name": "J. Adrio", "authorId": "37903974"}, {"name": "A. Demain", "authorId": "3631952"}], "n_citations": 635}, "snippets": ["E. coli has been extensively used as a recombinant host for many reasons including (i) ease of quickly and precisely modifying the genome; (ii) rapid growth to high cell densities; (iii) ease of culture in cheap media; and (iv) ease of reduction of protease activity. E. coli can accumulate heterologous proteins up to 50% of its dry cell weight [88]."], "score": 0.765625}, {"id": "(Kheirabadi et al., 2021)", "paper": {"corpus_id": 237336823, "title": "Cloning, Expression, and Purification of Recombinant Mouse Interferon-\u03b3", "year": 2021, "venue": "Research in Molecular Medicine", "authors": [{"name": "Seyedeh Elham Badiee Kheirabadi", "authorId": "2124756425"}, {"name": "Kazem Mashayekhi", "authorId": "39713298"}, {"name": "M. Moghadam", "authorId": "37476979"}, {"name": "M. Mousavi", "authorId": "46188576"}, {"name": "M. Sankian", "authorId": "3598806"}], "n_citations": 0}, "snippets": ["Because of its short life cycle, easy genetic manipulation, and simple culture conditions, E. coli is a preferable host to produce many recombinant proteins (Abdi et al., 2019)(Maleki et al., 2020)", "Although all bacteria could be used for recombinant protein technologies, E. coli is still the preferable host for the industrial production of recombinant proteins (Terpe, 2006)."], "score": 0.71533203125}, {"id": "(Abdi et al., 2019)", "paper": {"corpus_id": 199075971, "title": "Optimization of Cloning Conditions for High-level Production of Recombinant Mouse Interleukin-2 in Escherichia coli", "year": 2019, "venue": "Research in Molecular Medicine", "authors": [{"name": "A. Abdi", "authorId": "2063939362"}, {"name": "Mitra Hosseinpour", "authorId": "4970013"}, {"name": "Kazem Mashayekhi", "authorId": "39713298"}, {"name": "M. Mousavi", "authorId": "46188576"}, {"name": "Seyedeh Elham Badiee Kheirabadi", "authorId": "151366244"}, {"name": "M. Sankian", "authorId": "3598806"}], "n_citations": 5}, "snippets": ["<jats:p>.</jats:p>"], "score": 0.0}, {"id": "(Mitchell et al., 2021)", "paper": {"corpus_id": 237677625, "title": "Recombinant Protein Production with Escherichia coli in Glucose and Glycerol Limited Chemostats", "year": 2021, "venue": "Applied microbiology", "authors": [{"name": "A. M. Mitchell", "authorId": "1410490777"}, {"name": "V. Gogulancea", "authorId": "90579354"}, {"name": "Wendy Smith", "authorId": "47080561"}, {"name": "A. Wipat", "authorId": "1813523"}, {"name": "I. D. Ofi\u0163eru", "authorId": "6529906"}], "n_citations": 4}, "snippets": ["Escherichia coli alone accounts for the production of 30-40% of proteins approved for therapeutic use (Baeshen et al., 2015). Its well-characterised genome, the existence of many commercially available strains and their relatively low price, the high protein expression rates and the ease of performing genomic modifications to ensure high quality products explain the E. coli dominance amongst other microorganisms (Tripathi et al., 2019)3,(Zhang et al., 2016)."], "score": 0.90380859375}, {"id": "(Baeshen et al., 2015)", "paper": {"corpus_id": 7945842, "title": "Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.", "year": 2015, "venue": "Journal of Microbiology and Biotechnology", "authors": [{"name": "M. Baeshen", "authorId": "5192370"}, {"name": "A. Al-hejin", "authorId": "9760654"}, {"name": "R. Bora", "authorId": "3970322"}, {"name": "Mohamed M M Ahmed", "authorId": "122517033"}, {"name": "H. Ramadan", "authorId": "31915002"}, {"name": "K. Saini", "authorId": "34967342"}, {"name": "N. Baeshen", "authorId": "2766125"}, {"name": "E. Redwan", "authorId": "2361015866"}], "n_citations": 264}, "snippets": ["Escherichia coli is the most preferred microorganism to express heterologous proteins for therapeutic use, as around 30% of the approved therapeutic proteins are currently being produced using it as a host. Owing to its rapid growth, high yield of the product, cost-effectiveness, and easy scale-up process, E. coli is an expression host of choice in the biotechnology industry for large-scale production of proteins, particularly non-glycosylated proteins, for therapeutic use. The availability of various E. coli expression vectors and strains, relatively easy protein folding mechanisms, and bioprocess technologies, makes it very attractive for industrial applications. However, the codon usage in E. coli and the absence of post-translational modifications, such as glycosylation, phosphorylation, and proteolytic processing, limit its use for the production of slightly complex recombinant biopharmaceuticals. Several new technological advancements in the E. coli expression system to meet the biotechnology industry requirements have been made, such as novel engineered strains, genetically modifying E. coli to possess capability to glycosylate heterologous proteins and express complex proteins, including full-length glycosylated antibodies. This review summarizes the recent advancements that may further expand the use of the E. coli expression system to produce more complex and also glycosylated proteins for therapeutic use in the future."], "score": 0.0}, {"id": "(Marschall et al., 2016)", "paper": {"corpus_id": 18974150, "title": "Tunable recombinant protein expression in E. coli: enabler for continuous processing?", "year": 2016, "venue": "Applied Microbiology and Biotechnology", "authors": [{"name": "Lukas Marschall", "authorId": "49334253"}, {"name": "P. Sagmeister", "authorId": "3060941"}, {"name": "C. Herwig", "authorId": "2349044"}], "n_citations": 35}, "snippets": ["E. coli emerged as the primary production workhorse for the biotechnological production of primary and secondary metabolites as well as recombinant proteins. This is reflected by the fact that 29 % of all biopharmaceutical products approved as biopharmaceuticals between 2010 and July 2014 are produced in E. coli (Walsh, 2000)", "researchers today have access to a broad spectrum of genetic tools and cultivation techniques, enabling simple and predictable genetic manipulation and cultivation on inexpensive media to high cell densities."], "score": 0.79052734375}, {"id": "(Chen et al., 2025)", "paper": {"corpus_id": 276480527, "title": "Using Large Language Model to Optimize Protein Purification: Insights from Protein Structure Literature Associated with Protein Data Bank", "year": 2025, "venue": "Advancement of science", "authors": [{"name": "Zhuojian Chen", "authorId": "2347033884"}, {"name": "J. Sivaraman", "authorId": "2280114455"}], "n_citations": 1}, "snippets": ["E. coli remains the most widely used system for recombinant protein expression due to its numerous advantages over other expression systems such as yeast, baculovirus, mammalian cells, and cell-free systems. The key benefits of using E. coli include its low cost, ease of use, and ability to scale production efficiently, making it the preferred host for many researchers."], "score": 0.892578125}], "table": null}, {"title": "Economic Disadvantages and Limitations", "tldr": "Despite its economic advantages, E. coli has significant limitations for recombinant protein production, particularly its inability to perform post-translational modifications like glycosylation and difficulties with proper protein folding. These limitations often necessitate using more expensive eukaryotic expression systems for complex proteins, especially those requiring specific modifications for biological activity. (5 sources)", "text": "\nWhile E. coli offers numerous economic advantages for industrial-scale protein production, several inherent limitations can offset these benefits for certain applications. The most significant limitation is E. coli's inability to perform many post-translational modifications found in eukaryotic proteins, particularly glycosylation. This fundamental constraint means that proteins requiring these modifications for proper function cannot be effectively produced in bacterial systems. <Paper corpusId=\"237220817\" paperTitle=\"(Makrides, 1996)\" isShortName></Paper> <Paper corpusId=\"16496697\" paperTitle=\"(Daniell et al., 2001)\" isShortName></Paper>\n\nProtein folding issues represent another major economic disadvantage of E. coli expression systems. Human proteins expressed at high levels in E. coli frequently acquire unnatural conformations due to the lack of proper folding machinery and inability to form correct disulfide bridges. This often results in intracellular precipitation and the formation of inclusion bodies, where the protein is biologically inactive. <Paper corpusId=\"16496697\" paperTitle=\"(Daniell et al., 2001)\" isShortName></Paper> <Paper corpusId=\"4473355\" paperTitle=\"(Ferreira et al., 2018)\" isShortName></Paper> The presence of inclusion bodies necessitates additional downstream processing steps to recover and refold the protein, significantly increasing production costs and reducing yields.\n\nAnother economic challenge stems from E. coli's secretion limitations. Unlike some eukaryotic systems that can secrete proteins into the culture medium, recombinant proteins in E. coli typically remain intracellular. This lack of efficient secretion mechanisms makes downstream processing more complex and expensive, as cell disruption is required to access the protein, followed by more extensive purification procedures. <Paper corpusId=\"4473355\" paperTitle=\"(Ferreira et al., 2018)\" isShortName></Paper>\n\nThe bacterial endotoxin problem presents additional economic hurdles, particularly for therapeutic protein production. The lipopolysaccharides that constitute E. coli's outer membrane elicit strong immune responses in humans and other mammals, requiring stringent and costly purification procedures to ensure product safety for clinical applications. <Paper corpusId=\"4473355\" paperTitle=\"(Ferreira et al., 2018)\" isShortName></Paper> <Paper corpusId=\"1585460\" paperTitle=\"(Rosano et al., 2014)\" isShortName></Paper>\n\nTranslation efficiency issues can also undermine the economic benefits of E. coli systems. Differences in codon usage between foreign genes and native E. coli genes can lead to translation stalling or protein truncation, resulting in low expression levels or loss of function. While codon optimization strategies exist, they add complexity and cost to the development process. <Paper corpusId=\"237220817\" paperTitle=\"(Makrides, 1996)\" isShortName></Paper> <Paper corpusId=\"4473355\" paperTitle=\"(Ferreira et al., 2018)\" isShortName></Paper>\n\nDue to these limitations, certain valuable proteins simply cannot be produced in a biologically active form in bacterial systems. Notable examples include erythropoietin and anti-hemophilic factor VIII, which must be produced in mammalian cell cultures despite their higher production costs. <Paper corpusId=\"87012978\" paperTitle=\"(Kaliyeva et al., 2015)\" isShortName></Paper> Even for proteins that can be expressed in multiple systems, such as G-CSF, expression in the homologous host (mammalian cells for human proteins) often provides a product with superior properties for end-users, justifying the higher production costs in certain applications. <Paper corpusId=\"87012978\" paperTitle=\"(Kaliyeva et al., 2015)\" isShortName></Paper>\n\nWhile many eukaryotic proteins retain their full biological activity in non-glycosylated form and can therefore be successfully produced in E. coli, the economic advantages of bacterial expression must be carefully weighed against these limitations for each specific protein target. <Paper corpusId=\"237220817\" paperTitle=\"(Makrides, 1996)\" isShortName></Paper>", "citations": [{"id": "(Makrides, 1996)", "paper": {"corpus_id": 237220817, "title": "Strategies for achieving high-level expression of genes in Escherichia coli", "year": 1996, "venue": "", "authors": [{"name": "S. Makrides", "authorId": "3826647"}], "n_citations": 88}, "snippets": ["The many advantages of Escherichia coli have ensured that it remains a valuable organism for the high-level production of recombinant proteins (177a, 197, 254, 362, 406, 426, 510). However, in spite of the extensive knowledge on the genetics and molecular biology of E. coli, not every gene can be expressed efficiently in this organism. This may be due to the unique and subtle structural features of the gene sequence, the stability and translational efficiency of mRNA, the ease of protein folding, degradation of the protein by host cell proteases, major differences in codon usage between the foreign gene and native E. coli, and the potential toxicity of the protein to the host. Fortunately, some empirical \"rules\" that can guide the design of expression systems and limit the unpredictability of this operation in E. coli have emerged. The major drawbacks of E. coli as an expression system include the inability to perform many of the posttranslational modifications found in eukaryotic proteins, the lack of a secretion mechanism for the efficient release of protein into the culture medium, and the limited ability to facilitate extensive disulfide bond formation. On the other hand, many eukaryotic proteins retain their full biological activity in a nonglycosylated form and therefore can be produced in E. coli (see, e.g., references 170, 342, and 486)."], "score": 0.7958984375}, {"id": "(Daniell et al., 2001)", "paper": {"corpus_id": 16496697, "title": "Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants", "year": 2001, "venue": "Trends in Plant Science", "authors": [{"name": "H. Daniell", "authorId": "2072154602"}, {"name": "S. Streatfield", "authorId": "6290025"}, {"name": "K. Wycoff", "authorId": "4658660"}], "n_citations": 785}, "snippets": ["The use of microorganisms such as bacteria permits manufacture on a larger scale, but introduces the disadvantage of producing products that differ appreciably from the products of natural origin. For example, proteins that are usually glycosylated in humans are not glycosylated by bacteria. Furthermore, human proteins that are expressed at high levels in E. coli frequently acquire an unnatural conformation accompanied by intracellular precipitation, owing to lack of proper folding and disulfide bridges."], "score": 0.75341796875}, {"id": "(Ferreira et al., 2018)", "paper": {"corpus_id": 4473355, "title": "Techno-economic analysis of the industrial production of a low-cost enzyme using E. coli: the case of recombinant \u03b2-glucosidase", "year": 2018, "venue": "Biotechnology for Biofuels", "authors": [{"name": "R. Ferreira", "authorId": "46414338"}, {"name": "A. Azzoni", "authorId": "3315803"}, {"name": "S. Freitas", "authorId": "37552179"}], "n_citations": 123}, "snippets": ["The main advantages of using E. coli are well known, such as the ability of E. coli to grow rapidly on simple and inexpensive media, the ability of this bacteria to grow to high cell densities and achieve high levels of protein expression, the availability of strains with low proteolytic activities, and the large body of scientific knowledge concerning the physiology, genetics, and manipulation of E. coli (Demain et al., 2009)(Choi et al., 2006)(Terpe, 2006)(Waegeman et al., 2011)(Rosano et al., 2014). However, E. coli also presents disadvantages with respect to recombinant protein production: normally, the protein is not secreted by the cell, which often makes downstream processing more complex and expensive; the recombinant protein may aggregate and form insoluble particles called inclusion bodies, in which the protein is inactive; disulfide bonds may not form as intended, leading to protein denaturation and often to the formation of inclusion bodies; the cell machinery may stall or truncate proteins owing to codon bias, leading to low expression or loss of function; E. coli is not capable of performing post-translational modifications such as glycosylation; and the lipopolysaccharides that constitute the outer membrane of E. coli elicit strong immune responses in humans and other mammals [17][18][19][20][21]."], "score": 0.69921875}, {"id": "(Rosano et al., 2014)", "paper": {"corpus_id": 1585460, "title": "Recombinant protein expression in Escherichia coli: advances and challenges", "year": 2014, "venue": "Frontiers in Microbiology", "authors": [{"name": "Germ\u00e1n L. Rosano", "authorId": "40548489"}, {"name": "E. Ceccarelli", "authorId": "40501475"}], "n_citations": 2165}, "snippets": ["Escherichia coli is one of the organisms of choice for the production of recombinant proteins. Its use as a cell factory is well-established and it has become the most popular expression platform. For this reason, there are many molecular tools and protocols at hand for the high-level production of heterologous proteins, such as a vast catalog of expression plasmids, a great number of engineered strains and many cultivation strategies. We review the different approaches for the synthesis of recombinant proteins in E. coli and discuss recent progress in this ever-growing field."], "score": 0.0}, {"id": "(Kaliyeva et al., 2015)", "paper": {"corpus_id": 87012978, "title": "DEVELOPMENT OF AUTONOMOUSLY REPLICATING VIRAL RNA TO EXPRESS THE RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR", "year": 2015, "venue": "", "authors": [{"name": "M. Kaliyeva", "authorId": "122464682"}, {"name": "A. Shustov", "authorId": "12803202"}], "n_citations": 0}, "snippets": ["Escherichia coli is the most commonly used host for the production of recombinant proteins including the industrial technologies. However, some valuable proteins cannot be produced in a biologically active form in bacteria. These include, among others, the erythropoietin and the anti-hemophilic factor VIII, which are produced for medical use in the mammalian cell cultures. For other pharmacologically active proteins, such as G-CSF, a variety of production systems are available-employing expression in bacteria, yeast, plants, and cultured animal cells. Still, expression in homologous host often provides product with better properties for the end-user."], "score": 0.7958984375}], "table": null}, {"title": "Direct Economic Comparisons with Alternative Hosts", "tldr": "Direct economic comparisons consistently position E. coli as the most cost-effective expression system, delivering recombinant proteins at significantly lower costs than both mammalian cell culture and yeast-based systems. The cost advantages arise from E. coli's combination of inexpensive media requirements, rapid growth rates, high expression levels, and streamlined processing, which collectively create substantial economic benefits for industrial applications. (9 sources)", "text": "\nWhen directly comparing the economics of various expression systems, E. coli consistently emerges as the most cost-effective host for recombinant protein production at industrial scales. The economic benefits of E. coli become particularly evident when contrasting it with mammalian cell culture systems, which represent the primary alternative for biopharmaceutical manufacturing. While mammalian cells are necessary for proteins requiring complex post-translational modifications, their production processes are significantly more expensive and time-consuming than bacterial systems <Paper corpusId=\"14322255\" paperTitle=\"(Blanco-Toribio et al., 2015)\" isShortName></Paper> <Paper corpusId=\"256211480\" paperTitle=\"(Blanco-Toribio et al._1, 2015)\" isShortName></Paper>.\n\nThe cost differential between E. coli and mammalian expression systems is substantial and multifaceted. Mammalian cell cultivation is characterized by low volumetric yields, long cultivation times, and requirements for expensive bioreactors and medium components, all of which significantly impact production costs. In contrast, bacterial processes utilize inexpensive media in which fast growth and high cell concentrations can be achieved, resulting in higher volumetric productivities and considerably lower manufacturing expenses <Paper corpusId=\"276466073\" paperTitle=\"(Vallejo et al., 2004)\" isShortName></Paper>.\n\nComparative studies consistently show that E. coli delivers higher protein yields than mammalian cells while requiring significantly less production time and resources <Paper corpusId=\"14322255\" paperTitle=\"(Blanco-Toribio et al., 2015)\" isShortName></Paper> <Paper corpusId=\"256211480\" paperTitle=\"(Blanco-Toribio et al._1, 2015)\" isShortName></Paper>. This productivity advantage translates directly to economic benefits, as higher yields combined with faster production cycles allow for more efficient use of manufacturing capacity and lower costs per unit of protein produced.\n\nWhen compared to yeast expression systems, E. coli also demonstrates clear economic advantages. While yeast grows faster than mammalian cells, yeast-based production is still more expensive than E. coli and can suffer from genetic instability and clonal variation that may affect production consistency <Paper corpusId=\"57192905\" paperTitle=\"(Burdette et al., 2018)\" isShortName></Paper>. E. coli typically achieves higher recombinant protein yields compared to yeast systems while maintaining lower production costs <Paper corpusId=\"196660066\" paperTitle=\"(Al-hejin et al., 2019)\" isShortName></Paper> <Paper corpusId=\"237101690\" paperTitle=\"(Rigi et al., 2021)\" isShortName></Paper>.\n\nThe economic benefits of E. coli extend beyond production costs to include process development and scale-up considerations. E. coli is widely recognized as the simplest, fastest, and most cost-effective recombinant expression system, with protocols for protein production routinely completed in a single day <Paper corpusId=\"31546198\" paperTitle=\"(Francis et al., 2010)\" isShortName></Paper>. This rapid development timeline represents a significant economic advantage over alternative systems, which typically require weeks or months to establish and optimize.\n\nThe industrial significance of these economic advantages is reflected in E. coli's market position, with approximately 30% of approved biopharmaceuticals being produced using this bacterial host <Paper corpusId=\"268523497\" paperTitle=\"(Koppl et al., 2024)\" isShortName></Paper> <Paper corpusId=\"7945842\" paperTitle=\"(Baeshen et al., 2015)\" isShortName></Paper>. Despite recent advances in alternative production systems, E. coli continues to compete effectively with both mammalian and non-mammalian hosts for new product approvals <Paper corpusId=\"268523497\" paperTitle=\"(Koppl et al., 2024)\" isShortName></Paper>.\n\nFor industrial applications that do not require complex post-translational modifications, the economic case for E. coli is particularly compelling. The system's combination of genetic simplicity, rapid growth, high-density cultivation, and cost-efficient media requirements creates a substantial cost advantage that is difficult for alternative expression systems to match <Paper corpusId=\"196660066\" paperTitle=\"(Al-hejin et al., 2019)\" isShortName></Paper> <Paper corpusId=\"237101690\" paperTitle=\"(Rigi et al., 2021)\" isShortName></Paper> <Paper corpusId=\"31546198\" paperTitle=\"(Francis et al., 2010)\" isShortName></Paper>.", "citations": [{"id": "(Blanco-Toribio et al., 2015)", "paper": {"corpus_id": 14322255, "title": "Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies", "year": 2015, "venue": "AMB Express", "authors": [{"name": "Ana Blanco-Toribio", "authorId": "1401238431"}, {"name": "Ana Alvarez-Cienfuegos", "authorId": "1398825836"}, {"name": "N. Sainz-Pastor", "authorId": "1401277010"}, {"name": "N. Merino", "authorId": "34907062"}, {"name": "M. Compte", "authorId": "144233748"}, {"name": "L. Sanz", "authorId": "145075472"}, {"name": "F. Blanco", "authorId": "143900481"}, {"name": "L. \u00c1lvarez-Vallina", "authorId": "1398825827"}], "n_citations": 3}, "snippets": ["Recombinant antibodies are used with great success in many different diagnostic and therapeutic applications. A variety of protein expression systems are available, but nowadays almost all therapeutic antibodies are produced in mammalian cell lines due to their complex structure and glycosylation requirements. However, production of clinical-grade antibodies in mammalian cells is very expensive and time-consuming. On the other hand, Escherichia coli (E. coli) is known to be the simplest, fastest and most cost-effective recombinant expression system, which usually achieves higher protein yields than mammalian cells. Indeed, it is one of the most popular host in the industry for the expression of recombinant proteins."], "score": 0.84716796875}, {"id": "(Blanco-Toribio et al._1, 2015)", "paper": {"corpus_id": 256211480, "title": "Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies", "year": 2015, "venue": "AMB Express", "authors": [{"name": "Ana Blanco-Toribio", "authorId": "1401238431"}, {"name": "Ana Alvarez-Cienfuegos", "authorId": "1398825836"}, {"name": "N. Sainz-Pastor", "authorId": "1401277010"}, {"name": "N. Merino", "authorId": "34907062"}, {"name": "M. Compte", "authorId": "144233748"}, {"name": "L. Sanz", "authorId": "145075472"}, {"name": "F. Blanco", "authorId": "143900481"}, {"name": "L. \u00c1lvarez-Vallina", "authorId": "1398825827"}], "n_citations": 0}, "snippets": ["Recombinant antibodies are used with great success in many different diagnostic and therapeutic applications. A variety of protein expression systems are available, but nowadays almost all therapeutic antibodies are produced in mammalian cell lines due to their complex structure and glycosylation requirements. However, production of clinical-grade antibodies in mammalian cells is very expensive and time-consuming. On the other hand, Escherichia coli (E. coli) is known to be the simplest, fastest and most cost-effective recombinant expression system, which usually achieves higher protein yields than mammalian cells. Indeed, it is one of the most popular host in the industry for the expression of recombinant proteins."], "score": 0.84716796875}, {"id": "(Vallejo et al., 2004)", "paper": {"corpus_id": 276466073, "title": "Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins", "year": 2004, "venue": "Microbial Cell Factories", "authors": [{"name": "L. F. Vallejo", "authorId": "40077396"}, {"name": "Ursula Rinas", "authorId": "2249734512"}], "n_citations": 3}, "snippets": ["Recombinant protein production in mammalian cells yields a biologically active protein with all the required posttranslational modifications. However, mammalian cell cultivation is characterized by low volumetric yields of the recombinant protein, long cultivation times and requirements for expensive bioreactors and medium components. All these points have a great impact on the production costs. On the other hand, bacterial cultivation processes are based on inexpensive media in which fast growth and high cell concentrations can be obtained. These high cell concentrations combined with higher production rates of the bacterial expression system result in higher volumetric productivities."], "score": 0.74560546875}, {"id": "(Burdette et al., 2018)", "paper": {"corpus_id": 57192905, "title": "Developing Gram-negative bacteria for the secretion of heterologous proteins", "year": 2018, "venue": "Microbial Cell Factories", "authors": [{"name": "Lisa A Burdette", "authorId": "18959724"}, {"name": "S. Leach", "authorId": "117224423"}, {"name": "Han Teng Wong", "authorId": "15311232"}, {"name": "D. Tullman-Ercek", "authorId": "1398379700"}], "n_citations": 92}, "snippets": ["Bacterial hosts offer fast growth, relative genetic simplicity, and genetic stability [15]. Gram-negative bacteria are attractive hosts for recombinant protein production because they are fast growing, easy to manipulate, and genetically stable in large cultures. However, the utility of these microbes would expand if they also could secrete the product at commercial scales. Secretion of biotechnologically relevant proteins into the extracellular medium increases product purity from cell culture, decreases downstream processing requirements, and reduces overall cost", "Mammalian cells, however, are slow growing, expensive to culture, have large batch to batch variations, and can be difficult to genetically engineer (Kim et al., 2011)(Datar et al., 1993). Yeasts typically are faster growing but can suffer from genetic instability and clonal variation (Caunt et al., 1988)."], "score": 0.84716796875}, {"id": "(Al-hejin et al., 2019)", "paper": {"corpus_id": 196660066, "title": "Plasmids for Optimizing Expression of Recombinant Proteins in E. coli", "year": 2019, "venue": "Plasmid", "authors": [{"name": "A. Al-hejin", "authorId": "9760654"}, {"name": "R. Bora", "authorId": "3970322"}, {"name": "Mohamed Ahmed", "authorId": "2299938259"}], "n_citations": 6}, "snippets": ["E. coli is a preferred expression system for production of heterologous proteins due to its well-characterized genetics, ease of genetic manipulation, availability of several plasmid vectors and engineered host strains, low manufacturing cost, high yield of recombinant proteins as compared to other expression systems including yeast, mammalian cell lines, transgenic plants and transgenic animals."], "score": 0.91259765625}, {"id": "(Rigi et al., 2021)", "paper": {"corpus_id": 237101690, "title": "Optimization of expression, purification and secretion of functional recombinant human growth hormone in Escherichia coli using modified staphylococcal protein a signal peptide", "year": 2021, "venue": "BMC Biotechnology", "authors": [{"name": "G. Rigi", "authorId": "5164152"}, {"name": "A. Rostami", "authorId": "153507527"}, {"name": "Habib Ghomi", "authorId": "2123359136"}, {"name": "G. Ahmadian", "authorId": "3630197"}, {"name": "V. S. Mirbagheri", "authorId": "2123359505"}, {"name": "M. Jeiranikhameneh", "authorId": "9647101"}, {"name": "M. Vahed", "authorId": "13654093"}, {"name": "Sahel Rahimi", "authorId": "2123359958"}], "n_citations": 9}, "snippets": ["The advantages of this system include fast growth, high cell density using simple and low cost growth medium, known genetic information, availability of a large number of expression vectors and availability of mutant host strains, simple transfer, easy control, possibility of mass production of recombinant proteins and thus cost-effectiveness. In the case of yeast and mammalian hosts, in most cases, protein production is much lower and more expensive than E. coli host is."], "score": 0.86572265625}, {"id": "(Francis et al., 2010)", "paper": {"corpus_id": 31546198, "title": "Strategies to Optimize Protein Expression in E. coli", "year": 2010, "venue": "Current Protocols in Protein Science", "authors": [{"name": "D. Francis", "authorId": "6257099"}, {"name": "R. Page", "authorId": "3495828"}], "n_citations": 235}, "snippets": ["In spite of the development of multiple nonbacterial recombinant expression systems over the last three decades (yeast, baculovirus, mammalian cell, cell free systems; see Table 5.24.1), Escherichia coli is still the preferred host for recombinant protein expression (Yin et al., 2007). The rationale is clear: E. coli is easy to genetically manipulate, it is inexpensive to culture, and expression is fast, with proteins routinely produced in one day. Moreover, protocols for isotope-labeling for NMR spectroscopy and selenomethionine incorporation for X-ray crystallography are well established, making it highly suitable for structural studies. Thus, E. coli has multiple, significant benefits over other expression systems including cost, ease-of-use, and scale."], "score": 0.7900390625}, {"id": "(Koppl et al., 2024)", "paper": {"corpus_id": 268523497, "title": "Modifications of the 5\u2019 region of the CASPONTM tag\u2019s mRNA further enhance soluble recombinant protein production in Escherichia coli", "year": 2024, "venue": "Microbial Cell Factories", "authors": [{"name": "C. K\u00f6ppl", "authorId": "11989956"}, {"name": "Wolfgang Buchinger", "authorId": "2292131527"}, {"name": "G. Striedner", "authorId": "3190875"}, {"name": "M. Cserjan\u2010Puschmann", "authorId": "1403473552"}], "n_citations": 5}, "snippets": ["Escherichia coli is one of the most commonly used host organisms for the production of biopharmaceuticals, as it allows for cost-efficient and fast recombinant protein expression. Today, about 30% of approved biopharmaceuticals are produced by E. coli, and despite the recent advance of other production systems such as mammalian cell culture, new product approvals, like Beovu\u00ae and Cablivi R in 2019, are constantly being granted, allowing E. coli to compete with both mammalian and non-mammalian hosts (McElwain et al., 2022)(Baeshen et al., 2015)."], "score": 0.8154296875}, {"id": "(Baeshen et al., 2015)", "paper": {"corpus_id": 7945842, "title": "Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.", "year": 2015, "venue": "Journal of Microbiology and Biotechnology", "authors": [{"name": "M. Baeshen", "authorId": "5192370"}, {"name": "A. Al-hejin", "authorId": "9760654"}, {"name": "R. Bora", "authorId": "3970322"}, {"name": "Mohamed M M Ahmed", "authorId": "122517033"}, {"name": "H. Ramadan", "authorId": "31915002"}, {"name": "K. Saini", "authorId": "34967342"}, {"name": "N. Baeshen", "authorId": "2766125"}, {"name": "E. Redwan", "authorId": "2361015866"}], "n_citations": 264}, "snippets": ["Escherichia coli is the most preferred microorganism to express heterologous proteins for therapeutic use, as around 30% of the approved therapeutic proteins are currently being produced using it as a host. Owing to its rapid growth, high yield of the product, cost-effectiveness, and easy scale-up process, E. coli is an expression host of choice in the biotechnology industry for large-scale production of proteins, particularly non-glycosylated proteins, for therapeutic use. The availability of various E. coli expression vectors and strains, relatively easy protein folding mechanisms, and bioprocess technologies, makes it very attractive for industrial applications. However, the codon usage in E. coli and the absence of post-translational modifications, such as glycosylation, phosphorylation, and proteolytic processing, limit its use for the production of slightly complex recombinant biopharmaceuticals. Several new technological advancements in the E. coli expression system to meet the biotechnology industry requirements have been made, such as novel engineered strains, genetically modifying E. coli to possess capability to glycosylate heterologous proteins and express complex proteins, including full-length glycosylated antibodies. This review summarizes the recent advancements that may further expand the use of the E. coli expression system to produce more complex and also glycosylated proteins for therapeutic use in the future."], "score": 0.0}], "table": null}], "cost": 0.474591}}
